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To evaluate the economic efficiency of a Center of Excellence (CoE) care model 
for rheumatic diseases located in Bogotá-Colombia. Biomab CoE is based on an 
adaptation of Colombian clinical practice guideline for the management 
of rheumatoid arthritis (RA). Care standards are defined by the severity of the 
disease (DAS28), involving an interdisciplinary team and differential types and 
frequencies of health services for each level of severity [remission, low (LDA), 
moderate (MDA) and severe disease activity (SDA)]. A cost-analysis was 
conducted to analyze the health economic impact after the application of a CoE 
model in a cohort of RA patients followed during a year. Mean, minimum, and 
maximum treatment costs were calculated at different moments in time: baseline, 
follow-up at month six, and after a year. This was done by multiplying the number 
of patients at each cut-off by the estimated cost per stage of the disease, according 
to the recommendations of the Colombian Institute of Health Technology 
Assessment. Statistical analyses were performed using Microsoft Excel® and R. 
All estimated costs were expressed in United States dollars, using the 
average exchange rate from January to December of 2018, reported by Banco de 
la República de Colombia: US$1=$2,951.3 Colombian pesos(COP). As preliminary 
results, 968 patients were followed during a year. At the beginning of the follow-up, 
treating all patients in the CoE with an integral attention would cost 
COP$1,808,096,027 ($1,440,179,796-$3,601,084,711). Same number of patients 
treated at month six of follow-up would cost COP$1,377,186,140 ($1,127,818,822-
$2,570,342,964), and COP$1,147,370,864 ($949,470,612-$2,090,941,567) after a 
year of follow-up. Treating these patients in a CoE means potential cost-savings of 
up to COP$660,725,163 annually. As patients are treated in the CoE for RA, 
their health outcomes improve from severe disease activity status to low disease 
activity and remission, saving costs to the Colombian health system. 
 
